Chad Brown

Jul 05, 2017

NanoString Technologies has appointed Chad Brown senior vice president of sales and marketing. With more than 35 years of experience in life science tools and clinical diagnostics, Brown most recently served as the president and head of commercial operations for North America at Qiagen. Prior to that, Brown was with Roche Diagnostics Corporation, where he held a series of commercial leadership positions in the applied sciences and centralized diagnostics businesses. He has also held sales leadership positions in several medical device and healthcare companies, including Chiron Diagnostics, Rotech Healthcare, Apria Healthcare, and Humana.

Brown succeeds Barney Saunders, who is expected to stay with NanoString for a three-month transition period before pursuing other professional opportunities.

More Like This

Nov 20, 2017

Marc Eloit, Frederic Laurent, Olivier Lortholary, Robin Patel, Etienne Ruppé

PathoQuest has formed a scientific advisory board, comprising Marc Eloit, Frederic Laurent, Olivier Lortholary, Robin Patel, and Etienne Ruppé. Eloit is the founder of PatholQuest, a principal investigator at Institut Pasteur, and a professor of virology and former head of the virology unit at the Veterinary School of Maisons-Alfort. 

Laurent is a professor of microbiology at Hospices Civils de Lyon, while Lortholary is a professor and chair of the department of infectious and tropical diseases at  Hôpital Necker-Enfants Malades. Patel is chair of the division of clinical microbiology at the Mayo Clinic, and Ruppé is an assistant professor at the Hôpital Bichat. 

The SAB will advise PathoQuest on high-value medical applications for the firm's iDTECT Blood, an NGS-based metagenomic infectious disase diagnostic technology, it said. 

Nov 16, 2017

Charles Watts

Accelerate Diagnostics announced today the appointment of Charles Watts to its board of directors. He currently acts as a trustee on the Institute for Systems Biology Board in Seattle, Washington. Watts has served as director of Providence Health and Services from 2012 to 2016, chairing the Quality and Patient Safety Improvement Committee. He previously served as CMO at the Northwestern Memorial Hospital and associate dean for clinical affairs at the Feinberg School of Medicine from 2001 to 2011.

Nov 16, 2017

Joel Kanter

Medite Cancer Diagnostics has appointed Joel Kanter to the company’s board of directors as an independent director. Kanter has more than 30 years of experience in the financial services industry, providing financing to businesses that have included startups, early-stage development companies, and larger enterprises. Since 1986, Kanter has served as president of Windy City, a privately held investment firm, and he previously served as the president and CEO of Walnut Financial Services.

Nov 15, 2017

Mitch Levine

OncoCyte said that Mitch Levine has been appointed chief financial officer. Prior to joining OncoCyte, Levine was managing partner of Kirby Cover Capital Advisors, which provides consulting to international life sciences investment funds regarding US-based companies. In 2002 Levine founded Enable Capital Management. Prior to that, he was a founding member of The Shemano Group. He has also worked for Bear Stearns and Lehman Brothers.

Nov 14, 2017

Samuel Riccitelli, David Cohen

Precipio has appointed Samuel Riccitelli as chairman, replacing Robert Patzig who resigned after seven years on the board of Transgenomic, which recently merged with Precipio. Also, David Cohen was elected as a new director at Precipio to fill an existing vacancy. 

Riccitelli has been on Precipio's board since June. From October 2012 through February 2017, he was president and CEO of Signal Genetics, where he also was a director. Before that, he was executive vice president and COO of Genoptix.

Cohen is COO and co-owner of Standard Oil of Connecticut, and has founded several ventures, including My Gene Counsel, a cancer bioinformatics company.

Nov 13, 2017

Uta Francke, Val Sheffield, Kevin Campbell, Howard Worman, Benjamin Tycko

MNG Laboratories has appointed five individuals to its scientific advisory board. They are Uta Francke, Val Sheffield, Kevin Campbell, Howard Worman, and Benjamin Tycko. 

Francke is a professor emerita of genetics at Stanford University, while Sheffield is a professor of pediatrics and ophthalmology, and director of the division of medical genetics at the University of Iowa Carver College of Medicine.

Campbell is an investigator at the Howard Hughes Medical Institute, and chair and department executive officer in the department of molecular physiology and biophysics at the University of Iowa Carver College of Medicine. Worman is a professor of medicine and pathology and cell biology at the College of Physicians and Surgeons at Columbia University, while Tycko is senior scientist in the department of biomedical reearch, division of genetics and epigenetics at Hackensack University Medical Center. 

Nov 13, 2017

Chris Connelly, Brad Hunsley, Carissa Moore, Subodh Nimkar, John Scholl

Streck announced five new members of its leadership team: 

  • Chris Connelly, director of R&D for new product development/molecular. Connelly joined Streck in 2010 and was previously R&D scientific manager for the molecular division. 
  • Brad Hunsley, director of R&D for application development/existing products. Hunsley joined Streck in 1989, has held various leadership positions, and is currently a member of the company's scientific advisory committee.
  • Carissa Moore, director of R&D for new product development/stabilization and flow cytometry. Moore joined Streck in 2011 as an R&D scientist, and she served as R&D scientific manager from 2016 to 2017.
  • Subodh Nimkar, director of strategic marketing. Nimkar most recently served as a North America marketing programs manager at Agilent Technologies.
  • John Scholl, director of R&D for application development/private label products. Scholl joined Streck's R&D department in 1987 as a technician and was promoted to various supervisory positions in the department.
Nov 13, 2017

Annalisa Jenkins

PlaqueTec has appointed Annalisa Jenkins its CEO. She will lead the company's launch in 2018 of its biomarker-based PlaqueTec Liquid Biopsy System, which is being developed to improve risk assessment and enable earlier intervention in the management of coronary artery disease. The system collects biomarkers directly associated with plaques whtin coronary arteries in order to assess residual inflammatory risk. Jenkins formerly was the CEO of Dimension Therapeutics. Prior to that, she was Executive Vice President, Head of Global R&D for Merck Serono.

Nov 13, 2017

Eric Johnson, Ashley Kiley

Tenet Diagnostics has appointed Eric Johnson as director of laboratory services and Ashley Kiley as director of provider relations. Johnson is joining Tenet from Advanced Clinical Laboratory Solutions (ACLS), where he serves as laboratory director. He has also been a laboratory director at Iverson Genetics and Parabase Genomics. Kiley will also join Tenet from ACLS, where she serves as sales director. She has also served as a marketing manager for Pain Physicians NY.

Nov 09, 2017

Doug Liu, Mark Gladwell, Laura Furmanski

Doug Liu is retiring from his role as senior vice president of global operations at Qiagen, CEO Peer Schatz said during an earnings call this week. He will be succeeded by Mark Gladwell, who joined the company from Alere, where he most recently served as senior vice president of global operations. 

In addition, Schatz said that Laura Furmanski, senior vice president of the bioinformatics business area, has resigned from the company. A search for her successor is in an advanced stage, Schatz said.

Nov 08, 2017

Stephen Von Rump, Austin Lewis

Medite Cancer Diagnostics has appointed Stephen Von Rump as its CEO and Austin Lewis as the chairman of the company's board. Both appointments were effective immediately. They replace David Paterson, who resigned on Nov. 5 as Medite's CEO and chairman. Von Rump was previously the chief commercialization and strategy officer for Medite. 

Nov 08, 2017

Nicholas Potter

Nicholas Potter joined Epigenomics as director of reimbursement and medical affairs, effective Nov. 1. In his position, he will create the firm's reimbursement strategy for its blood-based menu of methylated cancer detection technologies. Most recently, Potter was at MPLN as laboratory director of molecular diagnostics, CSO, and finally executive vice president of clinical affairs. 

Nov 07, 2017

Harold Rabinovitz

Dermtech announced today that it has appointed Harold Rabinovitz to its scientific advisory board. Rabinovitz currently serves as a volunatary clinical professor of dermatology at the University of Miami School of Medicine. 

Nov 06, 2017

Lily Sarafan

Home Care Assistance CEO Lily Sarafan has joined the board of Counsyl. She also serves on the boards of AI company Entefy, the Stanford Alumni Association, and the Berkeley Haas Center for Innovation Economies. 

Nov 06, 2017

Jorge Garces

Epigenomics has appointed Jorge Garces as president and CSO, effective Dec. 1. He will join the firm's executive board and oversee operations, R&D, clinical affairs, regulatory and quality. Prior to joining Epigenomics, Garces was CEO and president of AltheaDx. Before that, he held the same positions at Enigma Diagnostics. He also has held management positions at Hologic and GenMark Diagnostics, as well as Third Wave Technologies.